The Short Answer
Compounded semaglutide is no longer legal for routine dispensing to the general public. The FDA removed semaglutide from its drug shortage list in February 2025, ended grace periods for mass compounding by May 2025, and has been actively enforcing against non-compliant pharmacies and telehealth companies ever since.
However — and this is important — compounding is not completely banned. Narrow legal pathways still exist under specific conditions. Here's exactly what's still permitted and what isn't.
What Changed — A Plain English Timeline
- 2022–2024: Massive GLP-1 demand exceeded supply. FDA placed semaglutide and tirzepatide on its official drug shortage list. This legally allowed compounding pharmacies to produce these medications at scale — at $150–$300/month versus $1,000+ for branded versions.
- Late 2024: FDA removed tirzepatide from the shortage list. Compounding grace periods began.
- February 2025: FDA removed semaglutide from the shortage list. Grace periods for compounding began.
- May 2025: All grace periods ended. Mass compounding of semaglutide copies became non-compliant.
- March 3, 2026: FDA sent 30 warning letters to telehealth companies in a single day. Hims & Hers struck a deal with Novo Nordisk, agreeing to stop marketing compounded GLP-1s.
- April 30, 2026: FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — closing both large-scale compounding pathways permanently if finalized. Public comment period open through June 29, 2026.
What Is and Isn't Legal Right Now
Licensed state pharmacies can still compound semaglutide for individual patients with a valid prescription documenting a specific medical need — such as a documented allergy to an inactive ingredient or a non-standard dose requirement.
Large-scale outsourcing facilities that produced compounded GLP-1s in bulk for general distribution can no longer legally do so. This is the pathway that powered most telehealth compounding programs.
Tirzepatide compounding continues through 503A pharmacies for patients with documented clinical need. Court injunctions have also prevented full FDA shutdown of some 503B facilities for tirzepatide specifically.
Telehealth companies claiming their compounded versions are equivalent to or the same as Wegovy or Ozempic are in violation of FDA rules. This was a key violation cited in the March 2026 warning letters.
⚠️ Safety note: The FDA has received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide — many involving dosing errors from multi-dose vials. This is one reason the FDA has taken enforcement so seriously.
What This Means If You're Currently on Compounded GLP-1
If you are currently receiving compounded semaglutide or tirzepatide through a telehealth platform, here is what you should do:
- Contact your provider immediately and ask whether their pharmacy is operating under 503A patient-specific compounding with a documented clinical justification — or whether they were relying on 503B bulk compounding.
- Do not abruptly stop your medication without speaking to a licensed physician first. Stopping GLP-1 medications suddenly can have health implications.
- Ask about transition options — many providers are now offering branded Wegovy or Zepbound through manufacturer savings programs that can bring costs closer to what you were paying for compounded versions.
- Check if your provider received an FDA warning letter — if your telehealth company was among the 30 that received FDA warnings in March 2026, evaluate your options carefully.
Legal Affordable Options in 2026
The good news is that branded GLP-1 programs have become more affordable in 2026 than they were a year ago. Here are the most viable options:
Manufacturer Savings Programs
Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) both offer savings cards that can significantly reduce out-of-pocket costs for commercially insured patients. Some programs bring monthly costs down to $25–$99/month for eligible patients.
Medicare GLP-1 Bridge Program
Starting July 2026, a Medicare GLP-1 Bridge program is expected to cover Wegovy and Zepbound at a $50/month copay under Part D for eligible Medicare beneficiaries.
Telehealth Platforms with Branded Medications
Several telehealth platforms now offer FDA-approved branded GLP-1 medications through licensed physicians at competitive prices. These providers handle prior authorization, insurance coordination, and direct delivery — making the process significantly simpler than navigating a traditional pharmacy.
Find a Vetted GLP-1 Provider
Paragon Health Access features Enhance MD, Direct Meds, SkinnyRx, and Sprout Health — all reviewed for FDA compliance and operating within current legal frameworks.
Compare Providers →Frequently Asked Questions
The Bottom Line
The era of cheap, widely available compounded GLP-1 medications is effectively over for most patients. The FDA has made its position clear through enforcement actions, warning letters, and formal regulatory proposals.
For patients who relied on compounded GLP-1s for affordability, the transition to branded medications is real and the cost increase is significant. However, manufacturer savings programs, Medicare coverage beginning July 2026, and the expansion of telehealth platforms offering branded options are creating new affordable pathways that did not exist a year ago.
The most important thing you can do right now is talk to a licensed physician before making any changes to your medication — and choose a provider that is operating clearly within the current legal framework.
✅ Editorial note: Paragon Health Access only features providers offering FDA-authorized branded GLP-1 medications through licensed US physicians. We update our provider listings regularly to reflect current compliance standing. Last reviewed: May 2026.
Compare FDA-Authorized GLP-1 Programs
See our vetted provider directory — updated for 2026 regulatory changes.
View Providers →This article is for informational purposes only and does not constitute medical or legal advice. Regulatory landscape may change — always consult a licensed healthcare provider and verify current rules with your pharmacy or telehealth provider. Sources: FDA.gov, Pharmacy Times, Federal Register Docket 2026-08552.